Trial
NCT04089904
Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Chicago
Collaborators
—
Condition
Gastroesophageal Junction Adenocarcinoma
Intervention
Pembrolizumab Injection
Why stopped
Low accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-20